 |
| January
30, 2026 |
| Covering
Life Sciences Drugs, Diagnostics, Devices,
Digital Health |
|
|
|
* may need subscription to view |
 |
| Boston's
most flexible contract vivarium
lab space: Start with a few study
cages and grow. |
|
Learn More
→ |
|
|
- CBSET: Expands Leadership Team, Welcoming
Michael C. John as Chief Regulatory and
Innovation Officer (CRIO) More
- Concerto Biosciences: Signs Development and
Commercialization Agreement With Sacco System
to Advance Next-Generation Microbial
Ingredient Discovery More
- Fractyl Health: Compelling 6-Month
Randomized REMAIN-1 Midpoint Data Showing
Durable Weight Maintenance With Revita After
GLP-1 Discontinuation
More
More
- Immuto Scientific and University of
Wisconsin–Madison: Collaboration to Advance
Discovery of Novel Cancer Targets More
- Insilico Medicine: Up to 31.3% Body Weight
Loss, Insilico Medicine Nominates AI-Powered
GIPR Antagonist ISM0676 as Preclinical
Candidate, Showing Synergistic Efficacy in
Combination Therapy More
- NanoMosaic: Secures FDA Advanced
Manufacturing Technology (AMT) Designation for
Advanced Gene Therapy Analytics More
|
|
 |
 |
The
Charles River CFO Advantage
Reassessing your business plan?
We provide financial leadership.
Smart. Nimble. Flexible. |
|
Learn More
→ |
|
|
|
- Alexandria Scraps Fenway Lab Conversion
Plans More*
- Cycle Pharmaceuticals: Extension of Applied
Therapeutics Tender Offer More
- Get Full Access to BYTE51 Life Sciences
Intelligence for 50% Off More
- Harvard Bioscience: Strategic
Consolidation of Manufacturing Operations to
Improve Efficiency and Support Long-Term
Growth More
- Hologic: Financial Results for First Quarter
of Fiscal 2026 More
- LSN: Hot Investor Mandates (Updated 01/27) More
- Moderna: Strategic Collaboration With
Recordati to Globally Commercialize
Investigational Propionic Acidemia
Therapeutic (mRNA-3927) More
More
- More on Repertoire Decoding Autoimmunity in
$1.92B Eli Lilly Deal More*
More*
- New Women’s Sports Medicine Institute Backed
by $50M Targets Training, Pregnancy Care Gaps
More*
- Takeda, Still in a Vyvanse Slog, Lifts
Guidance As It Looks to New Wave of Growth More
|
|
|
 |
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
|
- An Architect of Boston’s Life Sciences
Ecosystem is Now at Harvard, Focused on
Happiness More*
- BioPharmGuy News: Biotech Magic, Funding
Folly, He's Crazy, Vaccines in Retrograde More
- Episode 26–04 Sea Stars and the Secrets of
Life Podcast
- From Diagnostics to Drug Development:
Scipher Medicine’s Three-Track Strategy for
High-Impact Immunology More
- Subscribe to LifeSci Startup for
Updates on US Startups More
- Takeda Is 'Not in Favor' of Trump’s MFN
Deals, CEO-Designate Says More*
More*
- The Big4Bio Podcast: Every Moment
Matters: Getting Better Insights on Target
and off Target Biology Mark Aspinall and Jim
Raymond Podcast
- 386: The High Stakes for Huntington’s
Patients Podcast
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
Feature your company |
| Apply
to have your company
showcased by Big4Bio |
|
|
|
|
|
 |
| Life
Sciences Talent and Consulting
Strategist George Quinn Named
Partner, Fractional Talent at
Slone Partners |
|
Learn More
→ |
|
|
- AI in Biotech: The New Frontier for
Leadership & Strategy More
- BioSpace Reveals Fresh Design With 2026
Hotbed Maps, Highlighting Life Sciences Hubs More
- Former FDA Deputies Land at Lilly, AbbVie;
Italy’s Angelini Has a New CEO More*
- From Seed to Series C: What
Investors Look for Beyond the Science More
- ICYMI: CEO’s Perspective: Big Moves Come
with Big Responsibility More
- ICYMI: CEO’s Perspective: The High Cost of
Job Hopping More
- ICYMI: Elevating Executive Presence: A
Blueprint for Life Sciences and Biotech
Leaders More
- M&A in Life Sciences: The Turning Tide –
Why Now is a Strategic Inflection for
Biopharma and Biotech More
- The Rise of Fractional Talent in Life
Sciences: What to Expect in 2026 More
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
